China will carry the heaviest burden of hepatocellular carcinoma (HCC) among the world’s eight major markets by 2034, with diagnosed incident cases reaching 264,000 that year. According to a report from GlobalData, that figure represents roughly 71% of the projected 370,000 total incident cases across the eight markets — the United States, France, Germany, Italy, Spain, the United Kingdom, Japan, and China.
China’s Share of the Liver Cancer Burden
The same pattern holds for five‑year diagnosed prevalent cases of HCC. The analysis projects that China will record 702,000 such cases by 2034, accounting for about 77% of the 910,000‑plus cases expected across all eight markets. This distribution mirrors both incident and prevalent measures, highlighting the country’s outsized role in the global HCC setting.
Across the eight major markets, diagnosed incident cases are projected to grow at an annual rate of 2.06%, rising from just over 306,000 in 2024 to approximately 370,000 by 2034. Five‑year diagnosed prevalent cases are expected to climb at an annual rate of 2.13%, moving from 750,000 in 2024 to more than 910,000 in 2034.
Obesity and Alcohol Use Shift the Picture
GlobalData attributes the slowing decline in HCC incidence partly to falling hepatitis B rates from mass vaccination and falling hepatitis C rates following the introduction of antiviral agents. The recent plateau, however, may instead reflect rising global obesity rates and shifting alcohol consumption patterns. This marks a notable departure from the historical view that liver cancer was primarily a viral hepatitis disease.
The shift in underlying causes mirrors broader public health transitions seen in other regions, where rising metabolic conditions have begun to offset gains from vaccination and antiviral treatments. In China, where hepatitis B vaccination has been widespread for decades, the growing influence of obesity and alcohol suggests that prevention strategies may need to evolve beyond infection control alone.
Related: Ankura Hospitals launches 120‑bed super‑specialty facility in Indore
The variation in underlying causes across the eight markets reflects differences in public health interventions and lifestyle trends. For instance, in countries with high hepatitis B vaccination coverage, such as China and Japan, the relative contribution of obesity and alcohol to HCC incidence is growing. This evolving epidemiology shows the need for adaptable public health strategies that address both infectious and non-infectious risk factors. GlobalData’s analysis provides a full view of the projected HCC burden, incorporating current trends in risk factors and population demographics.
Regardless of cause, case numbers are on an upward trajectory across the markets studied. The United States, France, Germany, Italy, Spain, the United Kingdom, Japan, and China together form the eight‑market group. China alone will account for roughly 71% of projected incident cases and about 77% of five-year prevalent cases by 2034, according to the analysis.
These trends imply a rising demand for diagnostic services and treatment capacity.
Policymakers will likely need to balance vaccination programs with initiatives targeting lifestyle‑related risk factors.